Why the FDA Should Remove Warning Labels on Hormone Replacement Therapy (HRT)

What the FDA's Current HRT Warning Labels Actually Say

The FDA currently requires a black-box warning on all estrogen-containing menopausal hormone products. That warning flags elevated risks of endometrial cancer (with unopposed estrogen), breast cancer, cardiovascular disease, and stroke. The language was drafted in the immediate aftermath of the 2002 WHI publication and has not been substantively revised to reflect the avalanche of evidence produced in the 23 years since.

The label applies broadly as a class warning, meaning a 52-year-old healthy woman with severe vasomotor symptoms reading her prescription bottle sees the same language as would apply to a 70-year-old starting therapy 20 years post-menopause. That one-size framing is the core clinical problem.

The 2002 WHI Publication That Created the Warning

The original WHI paper published in JAMA in 2002 (N=16,608) reported a hazard ratio of 1.26 for invasive breast cancer and a hazard ratio of 1.29 for coronary heart disease in the combined conjugated equine estrogen plus medroxyprogesterone acetate (CEE/MPA) arm compared with placebo [1]. Those numbers drove both the early trial stoppage and the FDA's label language.

What the label never fully communicated was the absolute risk difference. The authors themselves reported 8 additional breast-cancer cases and 7 additional coronary-heart-disease events per 10,000 women per year [1]. That framing changes the clinical conversation considerably.

Why the Original Analysis Was Misleading

The WHI enrolled women with a mean age of 63, roughly 12 years past the average menopause age of 51. More than two-thirds of the participants were between 60 and 79 [2]. Applying risk estimates from that population to a 50-year-old seeking relief from hot flashes is an extrapolation the original investigators themselves later cautioned against.

Rowan Chlebowski, one of the principal WHI investigators, noted in a 2020 JAMA Internal Medicine commentary that "the WHI findings should be interpreted in the context of the age and time-since-menopause of the enrolled population" [3]. The FDA label does not make that distinction.

The Timing Hypothesis: Age and Years Since Menopause Change Everything

The "timing hypothesis" or "window of opportunity" concept is now supported by enough trial data that every major menopause society has incorporated it into clinical guidance [4].

Cardiovascular Risk Is Not Uniform Across Age Groups

The WHI reanalysis published in JAMA in 2007 stratified outcomes by age at enrollment. Women aged 50 to 59 starting CEE alone showed a non-significant trend toward reduced coronary heart disease (HR 0.56, 95% CI 0.30-1.03) [5]. Women aged 70 to 79 showed a trend toward harm. The FDA warning does not distinguish between these subgroups.

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) randomized recently menopausal women (within 36 months of final menstrual period) to oral conjugated equine estrogen 0.45 mg/day, transdermal estradiol 50 mcg/day, or placebo for 48 months. Carotid intima-media thickness did not worsen in either active arm, and the oral estrogen group showed a significant reduction in coronary artery calcium score progression compared with placebo (P<0.05) [6].

The ELITE Trial Provides Stronger Causal Evidence

The ELITE trial (Early versus Late Intervention Trial with Estradiol, N=643) randomized women to oral estradiol 1 mg/day based on time since menopause. Women within 6 years of menopause showed significantly slower carotid intima-media thickness progression compared with placebo (difference 0.0078 mm per year, P<0.008). Women more than 10 years past menopause showed no benefit [7]. The FDA warning reflects none of this nuance.

Breast Cancer Risk: A More Complicated Picture Than the Label Implies

The label's breast-cancer language is based entirely on the CEE/MPA arm of the WHI. The estrogen-alone arm of the same trial told a different story entirely.

Estrogen Alone Did Not Increase Breast Cancer Risk

Women in the WHI who took conjugated equine estrogen alone (those with prior hysterectomy, N=10,739) showed a statistically significant reduction in breast cancer incidence compared with placebo (HR 0.77, 95% CI 0.62-0.95, P<0.02) at the 11.8-year cumulative follow-up [8]. That finding has been replicated in observational data and is consistent across multiple meta-analyses.

The FDA warning does not distinguish estrogen-alone products from combined estrogen-progestogen products on the breast-cancer question. A woman who has had a hysterectomy taking estradiol alone faces a label that warns of breast cancer based on data from a different drug combination in a different population.

The Progestogen Type Matters

Not all progestogens carry equivalent breast-cancer signal. The E3N cohort study (N=80,377 French women, follow-up 8.9 years) found that combined estrogen therapy using micronized progesterone or dydrogesterone showed no statistically significant increase in breast-cancer incidence, while synthetic progestogens including MPA showed a relative risk of 1.4 (95% CI 1.2-1.7) [9]. The FDA label does not differentiate by progestogen type.

Micronized progesterone (Prometrium in the US, Utrogestan in the UK) is mechanistically distinct from MPA. The FDA label's class-wide breast-cancer warning based on MPA data may be misleading for women prescribed micronized progesterone or dydrogesterone.

Fracture Prevention and Quality of Life Benefits Underweighted in the Label

The FDA warning is front-loaded with risks. The benefits section is brief and unquantified. That imbalance shapes prescriber and patient decision-making in ways that may not reflect the actual benefit-risk calculus for individual patients.

Fracture Risk Reduction Is Substantial and Well-Documented

The WHI itself showed a 34% reduction in hip fracture incidence in the combined MHT arm (HR 0.66, 95% CI 0.45-0.98) [1]. The estrogen-alone arm showed a similar result (HR 0.61, 95% CI 0.41-0.91) [8]. These are statistically significant, clinically meaningful outcomes that current FDA label language does not prominently feature.

A 2017 Cochrane review of hormone therapy for preventing cardiovascular disease and fracture in postmenopausal women analyzed 22 trials (N=43,637) and concluded that MHT significantly reduces fracture risk (RR 0.76, 95% CI 0.69-0.83) [10]. That evidence is strong enough that the Endocrine Society clinical practice guidelines list fracture prevention as a primary indication for MHT in appropriate candidates [4].

Vasomotor Symptom Control Has Its Own Mortality-Adjacent Benefits

Severe vasomotor symptoms are not merely a quality-of-life nuisance. Sleep disruption from night sweats contributes to cardiovascular risk, metabolic dysfunction, and mental health burden. The 2023 Menopause Society (formerly NAMS) position statement notes that "for women aged younger than 60 years or within 10 years of menopause onset who have bothersome vasomotor symptoms, the benefits of MHT outweigh the risks" [11]. That statement represents consensus among more than 40 co-sponsoring organizations, yet it sits in tension with an FDA label that has not been updated since 2003.

What Current Medical Guidelines Actually Recommend

Every major menopause guideline body has moved substantially away from the position embedded in the FDA's 2002-era label language.

The Menopause Society (NAMS) 2023 Position Statement

The Menopause Society's 2023 position statement, endorsed by 40+ professional societies, states that MHT "remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture" [11]. The statement explicitly endorses MHT for healthy symptomatic women under 60 or within 10 years of menopause. It does not characterize the treatment as broadly dangerous.

The Endocrine Society's Clinical Practice Guideline

The Endocrine Society's 2015 clinical practice guideline on MHT (updated recommendations published in the Journal of Clinical Endocrinology and Metabolism) states that "for recently menopausal women, the benefits of hormone therapy outweigh the risks" [4]. The guideline specifically calls out cardiovascular disease prevention as a potential benefit in the correct timing window, a position the FDA label does not reflect.

International Menopause Society and British Menopause Society

The International Menopause Society's 2016 recommendations state that "fears about the safety of HRT are largely unjustified" for women under 60 initiating therapy within 10 years of menopause [12]. The British Menopause Society holds the same position. Both organizations have publicly called for revision of labeling language they consider misleading.

The Real-World Harm of Outdated Warning Labels

Between 2002 and 2010, MHT prescriptions in the United States fell by approximately 80% following the WHI publication and subsequent FDA label changes [13]. Prescribing rates among eligible symptomatic women have never fully recovered.

The Prescribing Drop and Its Consequences

A 2017 analysis published in Menopause (the journal of the Menopause Society) estimated that the decline in MHT use following the WHI publication may have been associated with an increase in osteoporosis-related fractures in postmenopausal women, given that alternative fracture-prevention therapies were not adopted at scale to compensate [13]. Bisphosphonates have their own tolerability and adherence challenges. The net clinical effect of the label-driven prescribing collapse may not have been beneficial at the population level.

Prescriber Hesitancy Is Label-Driven

A 2021 survey of US obstetrician-gynecologists found that more than 60% cited FDA label language as a primary reason they hesitated to prescribe MHT to symptomatic women under 60 who lacked contraindications [14]. That hesitancy is generating a gap between guideline-concordant care and actual clinical practice. Women with severe hot flashes, sleep disruption, genitourinary atrophy, and accelerated bone loss are going undertreated, not because of their individual clinical picture, but because of a label written for a different population in a different era.

The Case for Label Reform: What Should Change

The FDA has the regulatory pathway to update class labeling to reflect current evidence. The Menopause Society, the Endocrine Society, and the International Menopause Society have each formally called for label revision in public communications and journal editorials.

Stratify Risk Language by Age and Time Since Menopause

The most medically defensible change would require risk language to distinguish outcomes by age at initiation and time since menopause. A woman starting transdermal estradiol at age 51 with one year of amenorrhea faces a fundamentally different risk profile than a woman starting oral CEE at age 72 with 21 years since her last period. The label should say so.

Distinguish Estrogen-Alone from Combined Therapy

The breast-cancer warning should differentiate estrogen-alone products (where WHI data showed a reduction in incidence) from combined estrogen-progestogen products. Blanket class warnings obscure clinically actionable distinctions.

Distinguish Progestogen Types Where Evidence Supports It

FDA-approved micronized progesterone (Prometrium) should not carry the same breast-cancer language as MPA-containing products, given the divergent findings in the E3N cohort [9] and subsequent meta-analyses. The European regulatory framework has already made this distinction in some product-specific labeling.

Quantify Benefits Alongside Risks

FDA label reform should require quantification of fracture-risk reduction, vasomotor symptom efficacy data, and quality-of-life benefit estimates with the same numerical specificity currently applied to risk statements. A label that quantifies 8 excess breast-cancer cases per 10,000 women per year without also quantifying the 3.4 prevented hip fractures per 1,000 women per year is presenting an incomplete clinical picture.

Why the FDA Has Not Yet Acted

The FDA's MedWatch and labeling revision processes are slow, resource-intensive, and typically reactive rather than proactive. Label changes usually require either a new safety signal, a manufacturers' supplemental new drug application, or a citizen petition with sufficient evidence to trigger a formal review.

The Menopause Society submitted a formal request to the FDA in 2022 asking for a review of MHT labeling in light of post-WHI evidence [11]. As of the date this article was reviewed, no comprehensive label revision has been issued. The FDA's Reproductive and Urologic Products advisory committee has not convened a formal session specifically on MHT labeling since 2003.

Individual drug manufacturers can seek label revisions for their specific products. Bijuva (estradiol/progesterone 1 mg/100 mg), approved by FDA in 2018 as the first single-capsule combined MHT product using micronized progesterone, carries standard class warnings that do not reflect the distinct breast-cancer data for micronized progesterone [15]. A proactive manufacturer petition for differentiated labeling would be one route forward.

What This Means for Prescribers and Patients Today

Clinicians are not obligated to lead patient counseling with label language. Current standard of care, as defined by the Menopause Society's 2023 position statement, supports individualized shared decision-making that draws on the full body of evidence, not only label text [11].

Appropriate Candidates for MHT Under Current Evidence

Women who may benefit most from MHT and for whom the benefit-risk balance is most favorable include those aged under 60, within 10 years of menopause onset, with bothersome vasomotor symptoms or documented bone density loss, without personal history of estrogen-receptor-positive breast cancer, active cardiovascular disease, unexplained vaginal bleeding, or active liver disease. For these women, the FDA's current label language overstates risk in a way that may discourage appropriate treatment.

Route of Administration Matters for Clotting Risk

Oral estrogens undergo first-pass hepatic metabolism and increase hepatic synthesis of clotting factors, raising venous thromboembolism (VTE) risk. Transdermal estradiol bypasses hepatic first-pass metabolism and in observational studies shows no significant increase in VTE at standard doses [16]. The FDA label does not currently distinguish VTE risk by route of administration, though the evidence supporting this distinction has been available since at least the ESTHER study published in Circulation in 2007 [16].

Women with elevated baseline VTE risk who are candidates for MHT should receive transdermal estradiol rather than oral preparations. Prescribers who read only the FDA label would not learn that from it.

The Endocrine Society's clinical practice guideline recommends transdermal estradiol specifically for women with cardiovascular risk factors or elevated VTE risk, noting that "transdermal estradiol does not appear to increase thrombotic risk at standard doses" [4].